Loading...
XNYS
GKOS
Market cap6.25bUSD
Dec 04, Last price  
108.85USD
1D
1.29%
1Q
15.87%
Jan 2017
217.35%
IPO
288.75%
Name

Glaukos Corp

Chart & Performance

D1W1MN
XNYS:GKOS chart
P/E
P/S
16.29
EPS
Div Yield, %
Shrs. gr., 5y
5.10%
Rev. gr., 5y
10.10%
Revenues
383m
+21.85%
2,429,00020,946,00045,587,00071,700,000114,397,000159,254,000181,278,000236,984,000224,959,000294,011,000282,862,000314,711,000383,481,000
Net income
-146m
L+8.70%
-19,331,000-12,639,000-12,126,000-37,241,0004,522,000-92,000-12,951,00015,424,000-120,348,000-49,593,000-99,195,000-134,661,000-146,372,000
CFO
-61m
L+6.16%
-20,455,000-13,305,000-7,107,000-2,188,00012,309,00025,508,00018,864,000-369,000-22,988,00024,708,000-33,083,000-57,758,000-61,318,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
IPO date
Jun 25, 2015
Employees
783
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT